🇮🇳 India Stock Screener ← Switch market ⚡ HerAI

Sanofi India Limited SANOFI NSEPHARMA

Healthcare · Drug Manufacturers - General · India
https://www.sanofi.com/en/india/investors
Company Profile ↓
₹2,827.30
-42.83% 1Y
Mkt Cap₹6,511.45 Cr
P/E20.11
P/B8.21
Div. Yield4.13%
52W High₹5,118.23
52W Low₹2,827.30
Book Value₹358.69
EPS (TTM)₹140.59

Company Overview

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 40.3%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 58.5%.

Reasonable Valuation

Trades at a P/E of 20.1, below the sector median of 36.4.

Healthy Margins

Maintains a net profit margin of 17.9%.

Dividend Income

Offers a dividend yield of 4.13%.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of ₹1,823.40 Cr (-8.3% YoY); net profit ₹326.70 Cr.
  • Trailing 12 Months Year-on-year growth — revenue +7.7%, earnings +20.1%.
  • 5-Year Trend Long-term compounding — revenue CAGR -12.6%, profit CAGR -19.3%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-12.56%
1 Year:7.70%

Compounded Profit Growth

5 Years:-19.26%
1 Year:20.10%

Stock Price Performance

1 Year:-42.83%
6 Months:-17.60%
3 Months:-16.70%
1 Month:-8.12%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish
52-Week Range 0% of range
₹2,827.30 ₹5,118.23
Trend Signals
  • Price vs 50-DMABelow
  • Price vs 200-DMABelow
  • RSI (14)24.12 · Oversold
Price Performance
1M-8.12%
3M-16.70%
6M-17.60%
1Y-42.83%
Valuation vs Sector

P/E of 20.11 is below the sector median of 36.43 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

NSE TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Strong return on equity of 40.3%.
  • Healthy ROCE of 58.5%.
  • Attractive dividend yield of 4.13%.
  • Generates positive free cash flow.

CONS

  • Revenue declined at -12.6% CAGR over 5 years.
  • Earnings shrank at -19.3% CAGR over 5 years.
  • Trading 44.8% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).
  • RSI at 24 suggests oversold conditions.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
20.11
Industry PE
36.43
Forward P/E
15.76
PEG Ratio
-
Book Value
₹358.69
Price to Book
8.21
P/S
3.76
EV/EBITDA
13.84
Dividend Yield
4.13%

Growth (CAGR)

Revenue 5Y
-12.56%
Profit 5Y
-19.26%
Revenue (YoY)
7.70%
Earnings (YoY)
20.10%

Profitability & Returns

ROCE
58.48%
ROE
40.27%
ROA
21.09%
Profit Margin
17.94%
Op Margin
24.31%
Gross Margin
49.01%
EPS (Latest Qtr)
₹36.26
EPS (TTM)
₹140.59

Balance Sheet & Liquidity

Debt/Equity
1.78
Quick Ratio
1.05
Current Ratio
1.69
Debt
₹14.70 Cr
Total Assets
₹1,407.40 Cr
Current Assets
₹965.00 Cr
Working Capital
₹309.20 Cr

Ownership

Promoter Holding
60.60%
Chg in Prom Hold
-0.00%
FII / Inst Holding
22.97%
Chg in FII Hold
-1.55%

Financial Snapshot

Enterprise Value
₹6,511.45 Cr
Total Revenue (TTM)
₹1,805.20 Cr
EBITDA
₹477.50 Cr
Free Cash Flow
₹313.60 Cr
Operating Cash Flow
₹358.70 Cr
Shares Outstanding
₹2.30 Cr
Gross Margin
49.01%
Payout Ratio
87.49%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP ₹P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 SANOFI Sanofi India Limited NSEPHARMA 2,827.30 20.11 ₹6,511.45 Cr 4.13% 58.48% 40.27% -12.56% -19.26%
2 SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA 1,745.10 34.62 ₹4.19 L Cr 0.91% 17.94% 13.74% 10.39% 10.65%
3 DIVISLAB Divi's Laboratories Limited NSEPHARMA 9,190.00 83.58 ₹2.44 L Cr 0.32% 18.96% 15.32% 10.98% 12.08%
4 TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA 4,553.80 72.74 ₹1.73 L Cr 0.81% 9.05% 25.79% 13.27% 20.22%
5 ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA 1,117.30 24.90 ₹1.11 L Cr 0.09% 19.04% 18.59% 16.55% 36.99%
6 LENSKART Lenskart Solutions Limited NIFTY_MIDNSEPHARMA 631.35 164.41 ₹1.09 L Cr 0.00% 7.21% 5.65% 35.38% 66.99%
7 APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA 7,600.00 52.32 ₹1.09 L Cr 0.25% 19.20% 20.48% 14.85% 33.34%
8 LAURUSLABS Laurus Labs Limited NIFTY_MIDNSEPHARMA 2,012.50 99.48 ₹1.09 L Cr 0.12% 19.53% 16.77% 3.77% 4.00%
9 CIPLA Cipla Limited NIFTY50NSEAIPHARMA 1,314.00 31.51 ₹1.06 L Cr 0.99% 14.86% 11.27% 7.23% 11.45%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in INR.

Metric Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Dec 2025Mar 2026Jun 2026
Revenue 515.00 Cr491.00 Cr469.00 Cr511.00 Cr464.00 Cr--535.90 Cr406.30 Cr419.80 Cr472.30 Cr437.70 Cr
Cost of Revenue -------240.50 Cr208.70 Cr208.10 Cr234.30 Cr225.20 Cr
Gross Profit -------295.40 Cr197.60 Cr211.70 Cr238.00 Cr212.50 Cr
Operating Expenses 393.00 Cr377.00 Cr370.00 Cr374.00 Cr348.00 Cr--133.10 Cr111.80 Cr130.90 Cr104.20 Cr106.10 Cr
Operating Income 113.00 Cr105.00 Cr91.00 Cr128.00 Cr107.00 Cr--162.30 Cr85.80 Cr80.80 Cr133.80 Cr106.40 Cr
EBITDA 122.00 Cr114.00 Cr100.00 Cr137.00 Cr116.00 Cr--175.20 Cr103.60 Cr93.10 Cr147.20 Cr121.50 Cr
Interest Expense 1.00 Cr0000--30.00 L40.00 L60.00 L30.00 L30.00 L
Pretax Income 169.00 Cr186.00 Cr167.00 Cr169.00 Cr127.00 Cr--165.30 Cr94.10 Cr83.00 Cr137.90 Cr112.30 Cr
Tax Provision 45.63 Cr33.48 Cr30.06 Cr32.11 Cr24.13 Cr--45.80 Cr24.60 Cr21.30 Cr35.30 Cr28.80 Cr
Net Income 123.00 Cr152.00 Cr138.00 Cr137.00 Cr103.00 Cr--119.50 Cr69.50 Cr61.70 Cr102.60 Cr83.50 Cr
Diluted EPS 53.4366.0459.8759.3944.87--51.8930.1826.7944.5536.26

Profit & Loss (Annual)

Figures in INR.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -2,727.20 Cr1,981.60 Cr1,989.00 Cr1,823.40 Cr
Cost of Revenue -1,243.70 Cr967.10 Cr998.10 Cr905.90 Cr
Gross Profit -1,483.50 Cr1,014.50 Cr990.90 Cr917.50 Cr
Operating Expenses -817.90 Cr561.20 Cr537.20 Cr463.50 Cr
Operating Income -665.60 Cr453.30 Cr453.70 Cr454.00 Cr
EBITDA -907.90 Cr569.80 Cr471.10 Cr483.70 Cr
Interest Expense -1.70 Cr1.70 Cr1.50 Cr1.70 Cr
Pretax Income -864.30 Cr528.50 Cr431.40 Cr444.70 Cr
Tax Provision -243.70 Cr163.90 Cr117.70 Cr118.00 Cr
Net Income -620.60 Cr602.90 Cr413.50 Cr326.70 Cr
Diluted EPS -269.47261.78179.54141.85

Balance Sheet (Annual)

Figures in INR.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -2,071.70 Cr1,714.80 Cr1,611.80 Cr1,254.80 Cr
Current Assets -1,610.30 Cr1,248.00 Cr1,126.80 Cr800.60 Cr
Cash & Equivalents -1,004.90 Cr394.50 Cr283.80 Cr262.90 Cr
Inventory -408.00 Cr663.80 Cr499.80 Cr311.60 Cr
Receivables -129.10 Cr131.70 Cr230.00 Cr176.70 Cr
Total Liabilities -795.90 Cr699.60 Cr751.20 Cr505.60 Cr
Current Liabilities -740.60 Cr651.30 Cr736.50 Cr491.40 Cr
Long Term Debt -----
Total Debt -23.60 Cr19.00 Cr19.30 Cr17.80 Cr
Total Equity -1,275.80 Cr1,015.20 Cr860.60 Cr749.20 Cr
Shares Outstanding -2.30 Cr2.30 Cr2.30 Cr2.30 Cr

Cash Flows (Annual)

Figures in INR.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -398.70 Cr230.40 Cr461.70 Cr438.30 Cr
Investing Cash Flow -650.90 Cr37.50 Cr-19.20 Cr-11.30 Cr
Financing Cash Flow --1,582.70 Cr-878.30 Cr-392.40 Cr-447.90 Cr
Capital Expenditure --22.20 Cr-34.30 Cr-36.40 Cr-25.70 Cr
Free Cash Flow -376.50 Cr196.10 Cr425.30 Cr412.60 Cr
Net Change in Cash --533.10 Cr-610.40 Cr50.10 Cr-20.90 Cr

Ratios (Annual)

Figures in %.

Metric Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -54.4%51.2%49.8%50.3%
Operating Margin % -24.4%22.9%22.8%24.9%
Net Margin % -22.8%30.4%20.8%17.9%
ROE % -48.6%59.4%48.0%43.6%
ROCE % -50.0%42.6%51.8%59.5%

Shareholding Pattern

Insiders
60.60%
Institutions
22.97%
Public Float
58.30%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for SANOFI

Google News Mon, 19 Oct 2026

Why Recursion Pharmaceuticals Stock Is In Focus After Drug Data And Sanofi Milestone - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPbkxnMHE1TWRJVExDdEZNSENndTJFN3ZFWmNPSXhlYTU4YXhDUVNpTmFyaWxfNVlYSklKYTNGMzNDZ0pOSXZJeVRyRG9kLXJfMVRpS1pROTUzdUpSbkktZXNBQ1dMU1RCZkRfdHhyQnJiOENXZDA0Rmc3cHhLMVJHWWVvZHBpVW5ENEhJSk…

Google News Fri, 02 Oct 2026

Why is Sanofi stock sliding to a 52-week low today? - Investing.com

<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxPVnNvMWt3amdoNkctdjJ4SjFRcUVaUzNmVlcwNzFtNTJxU0YzMEw1amdwTDhGMkhreGY3THVPeDNNbUV6YzViTTA3T0t2Vmt1SGt3a3B6RDFYVjVUOEtSX3h5b3Q4VFFubzRHMnYzdzVFcFItczdKNUVTM0xWczdud0pZRnpzZGdJYm9ZN2…

Google News ue, 20 Oct 2026

Sanofi: Why The Market Seems To Be Overpricing Pipeline Risk (NASDAQ:SNY) - Seeking Alpha

<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxQZ0VNVUpGR3RBanZrWllmcVVjTzZZQkJuanVsZ2VXQjdkdEhxX0lvU3NVeEFqNFltek5WNFQ5WkJoQ3M5dGxGcUt5TU1JbGZLZnN4TmRzYjlEUnUxaTRiS2FMRFFRSmxLekp2ejdVZnZVNGI3MnF4ek5jZHU3ZFFKbFNUZU9fcFVxeGs3a2…

Google News hu, 01 Oct 2026

Sanofi, Regeneron expand tie-up with $8 billion drug-development deal, settle legal dispute - Euronext Markets: Real-time Stock Market Data | live

<a href="https://news.google.com/rss/articles/CBMiwgFBVV95cUxNTkNzOGticU1RUDVkSm0yT3ZBaWs1cmFnWEJ0ZW44bmRfNmRLTlZYNnctR0JiOTdKQUNxOE1tMTRZa24zZkx0eWJnMWMzQkFWUUw0SlI2Z2s3anFMZ0RxTGI3dnZjQ3BUUEZMYVdOQzd3OUtsZW9lYjJid1BsaFZINVVtQVJxNzlCaDVObF…

Google News ue, 20 Oct 2026

Is It Too Late to Buy Sanofi SA (SNY) After 4.6% Rally? GF Value Says Undervalued - GuruFocus

<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxPRnBYdC1GMlN1VFlMVGE3Qnl5Y2pDVm1YY05Ga0g0VmNqd2lnR0U2QzNiM0NfYmZyYWIwbUtsVlB4bk9ZaFl6dVhGdTlHTDdsZ1BtY2xQS2d0Rzl6RVdvSWk1SnRpM3BwOFRkWEJ4YU9DUTB4MWtIclNMMUZzUHVUTmtFZzF1ZWktQVd2cG…

Google News hu, 15 Oct 2026

Sanofi (ENXTPA:SAN) Stock Looks Reasonable After Its Antibody Deal - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxOUVMzNGphSlVjY2lkN05tTms3Rk9nNUE5a2RWVmRuZjNoOHpSUDZqRFZOTldmUG80a1VfeElEbzNJbWdJUkgta0RhOVVPRlhpVW52blJqT25xZVFDWldmNzlxdEc2QkFpNm1PS0VoeFBIT1VsS1dwVU9fMEVKQ2E5NzdkMXN0eU82Ylkyck…

SANOFI — Frequently Asked Questions

What is the current share price of Sanofi India Limited (SANOFI)?

As of 2026-10-23 04:58 IST, Sanofi India Limited (SANOFI) trades at ₹2,827.30 on NSE. Its 52-week range is ₹2,827.30 to ₹5,118.23.

What is the market capitalisation of SANOFI?

Sanofi India Limited (SANOFI) has a market capitalisation of ₹6,511.45 Cr on NSE.

What is the P/E ratio of SANOFI?

SANOFI trades at a trailing price-to-earnings (P/E) ratio of 20.11. The industry average P/E is 36.43. Its price-to-book (P/B) ratio is 8.21.

Does SANOFI pay a dividend?

Sanofi India Limited (SANOFI) currently offers a dividend yield of 4.13%.

What is the return on equity (ROE) of SANOFI?

SANOFI has a return on equity (ROE) of 40.27%. Its return on capital employed (ROCE) is 58.48%.

Is SANOFI a good stock to buy?

This page provides a data-driven analysis of Sanofi India Limited (SANOFI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All India Stocks
⚙Ad space